^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    INBRX-106

    i
    Other names: ES 102, INBRX106, INBRX 106, INBRX-106, ES102, ES-102
    Associations

    News

    Trials
    Company:
    Elpiscience, Inhibrx Biosci
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Elpiscience (Suzhou) Biopharma, Ltd.
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • INBRX-106
    3ms
    Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov)
    P2, N=12, Recruiting, Providence Health & Services | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2026 --> Jun 2027
    Enrollment open • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • INBRX-106
    5ms
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2; Phase classification: P1 --> P1/2
    Combination therapy • Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • INBRX-106
    7ms
    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
    P2/3, N=410, Recruiting, Inhibrx, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • INBRX-106
    8ms
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Completed, Elpiscience Biopharma, Ltd. | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
    Trial completion • Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    INBRX-106
    9ms
    Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Providence Health & Services
    New P2 trial • Combination therapy
    |
    Keytruda (pembrolizumab) • INBRX-106
    10ms
    INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC (clinicaltrials.gov)
    P2/3, N=410, Not yet recruiting, Inhibrx, Inc.
    New P2/3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • INBRX-106
    10ms
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Elpiscience Biopharma, Ltd. | Trial completion date: Mar 2024 --> Jun 2024
    Trial completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    INBRX-106
    10ms
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1; Phase classification: P1/2 --> P1
    Combination therapy • Phase classification • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • INBRX-106
    almost2years
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2 | N=333 | Recruiting | Sponsor: Inhibrx, Inc. | Phase classification: P1 ➔ P1/2 | N=200 ➔ 333
    Combination therapy • Enrollment change • Phase classification
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • INBRX-106
    almost2years
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1; Trial completion date: Mar 2024 --> Mar 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Combination therapy • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • INBRX-106
    2years
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Elpiscience Biopharma, Ltd. | N=36 --> 18 | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Sep 2022 --> Dec 2023
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    INBRX-106
    almost3years
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1; N=150 --> 200 | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Combination therapy • Trial completion date • Trial primary completion date • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • INBRX-106
    3years
    A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=146, Recruiting, Elpiscience Biopharma, Ltd. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    Loqtorzi (toripalimab-tpzi) • INBRX-106
    over3years
    A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=146, Not yet recruiting, Elpiscience Biopharma, Ltd.
    Clinical • New P1 trial • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    Loqtorzi (toripalimab-tpzi) • INBRX-106
    over3years
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Recruiting, Elpiscience Biopharma, Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    INBRX-106
    almost4years
    A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Elpiscience Biopharma, Ltd.
    Clinical • New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK rearrangement
    |
    INBRX-106